Globant, PharmaMar enter collaboration for cancer drug discovery

Globant (GLOB) and PharmaMar announced a new collaboration designed to speed up cancer drug discovery through artificial intelligence. Through Globant Enterprise AI, the two organizations have created a multi-agent AI system that delivers more than 90% accuracy in complex data retrieval and reduces time to insights up to 15-fold, helping scientists select high-potential drug candidates for clinical development in a fraction of the time previously required.